Articles dans des revues avec comité de lecture (38)
  1. 1. Lengrand, J., Pastushenko, I., Vanuytven, S., Song, Y., Venet, D., Sarate, R. M., Bellina, M., Moers, V., Boinet, A., Sifrim, A., Rama, N., Ducarouge, B., Van Herck, J., Dubois, C., Scozzaro, S., Lemaire, S., Gieskes, S., Bonni, S., Collin, A., Braissand, N., Allard, J., Zindy, E., Decaestecker, C., Sotiriou, C., Salmon, I., Mehlen, P., Voet, T., Bernet, A., & Blanpain, C. (2023). Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature (London). doi:10.1038/s41586-023-06372-2
  2. 2. Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm12030953
  3. 3. Cailleux, F., Agostinetto, E., Lambertini, M., Rothé, F., Wu, H.-T., Balcioglu, M., Kalashnikova, E., Vincent, D., Viglietti, G., Gombos, A., Papagiannis, A., Veys, I., Awada, A., Sethi, H., Aleshin, A., Larsimont, D., Sotiriou, C., Venet, D., & Ignatiadis, M. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology, 6, e2200148. doi:10.1200/PO.22.00148
  4. 4. Fimereli, D., Venet, D., Rediti, M., Boeckx, B., Maetens, M., Majjaj, S., Rouas, G., Marchio, C., Bertucci, F., Mariani, O., Capra, M., Bonizzi, G., Contaldo, F., Galant, C., Van den Eynden, G., Salgado, R., Biganzoli, E., Vincent-Salomon, A., Pruneri, G., Larsimont, D., Lambrechts, D., Desmedt, C., Brown, D. N., Rothé, F., & Sotiriou, C. (2022). Timing evolution of lobular breast cancer through phylogenetic analysis. EBioMedicine, 82, 104169. doi:10.1016/j.ebiom.2022.104169
  5. 5. Rothé, F., Venet, D., Peeters, D., Rouas, G., Rediti, M., Smeets, D., Dupont, F., Campbell, P., Lambrechts, D., Dirix, L. Y., Sotiriou, C., & Ignatiadis, M. (2022). Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ breast cancer, 8(1), 79. doi:10.1038/s41523-022-00445-7
  6. 6. Van Rees, D. D., Bouti, P., Klein, B., Verkuijlen, P. P., Van Houdt, M., Schornagel, K., Tool, A. A., Venet, D., Sotiriou, C., El-abed, S., Izquierdo, M., Guillaume, S., Saura, C., Di Cosimo, S., Huober, J., Roylance, R., Kim, S.-B., Kuijpers, T. W., Van Bruggen, R., K Van Den Berg, T., & Matlung, H. H. (2022). Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. Journal for ImmunoTherapy of Cancer, 10(6), e004820. doi:10.1136/jitc-2022-004820
  7. 7. Chang, C. A., Jen, J., Jiang, S., Sayad, A., Mer, A. S., Brown, K. R., Nixon, A. M. L., Dhabaria, A., Tang, K. H., Venet, D., Sotiriou, C., Deng, J., Wong, K. K., Adams, S., Meyn, P., Heguy, A., Skok, J. A., Tsirigos, A., Ueberheide, B., Moffat, J., Singh, A., Haibe-Kains, B., Khodadadi-Jamayran, A., & Neel, B. G. (2022). Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. Cancer Discovery, 12(4), 1022-1045. doi:10.1158/2159-8290.CD-20-1265
  8. 8. Gombos, A., Venet, D., Ameye, L., Vuylsteke, P., Neven, P., Richard, V., Duhoux, F. F., Laes, J.-F., Rothé, F., Sotiriou, C., Paesmans, M., Awada, A., Guiot, T., Flamen, P., Piccart-Gebhart, M., Ignatiadis, M., & Gebhart, G. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ breast cancer, 7(1), 125. doi:10.1038/s41523-021-00331-8
  9. 9. Venet, D., Rediti, M., Maetens, M. M., Fumagalli, D., Brown, D. N., Majjaj, S., Salgado, R., Pusztai, L., Harbeck, N., El-Abed, S., Wang, Y., Saura, C., Gomez, H., Semiglazov, V. F., de Azambuja, E., Huober, J., Nuciforo, P. G., Di Cosimo, S., Piccart-Gebhart, M., Loi, S., Rothé, F., & Sotiriou, C. (2021). Copy number aberration analysis to predict response to neoadjuvant antiHER2 therapy: results from the NeoALTTO phase III clinical trial. Clinical cancer research, 27(20), 5607-5618. doi:10.1158/1078-0432.CCR-21-1317
  10. 10. Aftimos, P., Oliveira, M., Irrthum, A., Fumagalli, D., Sotiriou, C., Nili Gal-Yam, E., Robson, M. M., Ndozeng, J., Di Leo, A., Ciruelos, E. M., de Azambuja, E., Viale, G., Scheepers, E. D., Curigliano, G., Bliss, J. M., Reis-Filho, J. S., Colleoni, M. A., Balic, M., Cardoso, F., Albanell, J., Duhem, C., Marreaud, S., Romagnoli, D., Rojas, B., Gombos, A., Wildiers, H., Guerrero-Zotano, A., Hall, P., Bonetti, A., Larsson, K. F., Degiorgis, M., Khodaverdi, S., Greil, R., Sverrisdottir, A., Paoli, M., Seyll, E., Loibl, S., Linderholm, B. B., Zoppoli, G., Davidson, N. E., Johannsson, O. T., Bedard, P. L., Loi, S., Knox, S., Cameron, D. A., Harbeck, N., Lasa Montoya, M., Brandão, M., Vingiani, A., Caballero, C., Hilbers, F. S., Yates, L. R., Benelli, M., Venet, D., & Piccart, M. J. (2021). Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer discovery. doi:10.1158/2159-8290.CD-20-1647
  11. 11. Richard, F., Majjaj, S., Venet, D., Rothé, F., Pingitore, J., Boeckx, B., Marchio, C., Clatot, F., Bertucci, F., Mariani, O., Galant, C., Eynden, G. V. D., Salgado, R., Biganzoli, E., Lambrechts, D., Vincent-Salomon, A., Pruneri, G., Larsimont, D., Sotiriou, C., & Desmedt, C. (2020). Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical cancer research, 26(23), 6254-6265. doi:10.1158/1078-0432.CCR-20-2268
  12. 12. Venet, D., Fimereli, D., Rothé, F., Boeckx, B., Maetens, M., Majjaj, S., Rouas, G., Capra, M., Bonizzi, G., Contaldo, F., Galant, C., Piccart, M., Pruneri, G., Larsimont, D., Lambrechts, D., Desmedt, C., & Sotiriou, C. (2020). Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. EBioMedicine, 56, 102793. doi:10.1016/j.ebiom.2020.102793
    13. << Précédent 1 2 3 4 Suivant >>